RAA Takes Companies from the Laboratory to Reality

Farmington Hills, MI -- Regulatory Affairs Associates (RAA)is a fast-growing Michigan-based firm that helps pharmaceutical and life science companies get new drugs and medical devices approved. RAA has grown exponentially since its founding in September 2001. A key reason for this is RAA’s successful track record with the FDA.

“Creating new drugs is both risky and expensive,” said Stephen J. Goldner, founder and President of RAA. “According to the New England Journal of Medicine, the average cost of developing a new drug is more than $860 million. We can help companies mitigate the risk by helping them to get their new drugs safely and efficiently through the development and approval process to the market.”

According to Goldner making it through the rigorous FDA approval process is a long and complicated process. The RAA team knows what the FDA wants done in order to approve medical break-through drugs and medical devices. Its list of client companies continues to grow given RAA’s reputation for gaining approval at the least cost and in the shortest time possible.

“At RAA our goal is to bring life-saving medical technologies to people in medical need by leveraging expensive research costs to reach marketable milestones,” he added.

In 2006, RAA expanded its operations to include a Drug and Medical Device Development Center in Ann Arbor, Michigan. This facility is currently initiating clinical trials on a promising potential therapeutic for skin cancer. As a result, RAA is adding to its team at a rapid pace.

RAA has developed four videos on key topics to make prospective clients, as well as the general public, more aware of major issues in the pharmaceutical industry. The newest video, Eureka, focuses on the issues and costs of guiding breakthrough research through the drug approval process. The video can be viewed at www.regaffairs.net.

###

Contact Information

Martha Welsh

Principal

M3 Strategies

Contact via E-mail